Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tim3”

42 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 42 results

Not applicableNot Yet RecruitingNCT07383805
What this trial is testing

Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis

Who this might be right for
Ankylosing SpondylitisASTim3
Assiut University 81
Testing effectiveness (Phase 2)Active Not RecruitingNCT04139902
What this trial is testing

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Who this might be right for
Melanoma Stage IIIMelanoma Stage IV
Diwakar Davar 48
Not applicableStudy completedNCT03549546
What this trial is testing

Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.

Who this might be right for
Lung CancerSurgery
Centre Hospitalier Universitaire de Saint Etienne 31
Testing effectiveness (Phase 2)Ended earlyNCT04823624
What this trial is testing

MBG453 in Lower Risk MDS

Who this might be right for
Myelodysplastic Syndromes
Massachusetts General Hospital 10
Early research (Phase 1)Study completedNCT05216835
What this trial is testing

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Classical Hodgkin Lymphoma
AstraZeneca 45
Early research (Phase 1)Study completedNCT03652077
What this trial is testing

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Who this might be right for
Cervical CancerGastric CancerStomach Cancer+18 more
Incyte Corporation 40
Not applicableStudy completedNCT02180009
What this trial is testing

Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis

Who this might be right for
SepsisSevere SepsisSeptic Shock
Chinese PLA General Hospital 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT03680508
What this trial is testing

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Who this might be right for
Adult Primary Liver CancerAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer
University of Hawaii 42
Testing effectiveness (Phase 2)Ended earlyNCT04812548
What this trial is testing

Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 20
Testing effectiveness (Phase 2)Study completedNCT04785820
What this trial is testing

Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Who this might be right for
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Hoffmann-La Roche 190
Testing effectiveness (Phase 2)Ended earlyNCT04623216
What this trial is testing

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Who this might be right for
Acute Myeloid Leukemia
Novartis Pharmaceuticals 24
Early research (Phase 1)Ended earlyNCT03940352
What this trial is testing

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 52
Large-scale testing (Phase 3)Study completedNCT01661257
What this trial is testing

Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

Who this might be right for
Crohn's Disease
Samsung Medical Center 20
Testing effectiveness (Phase 2)Ended earlyNCT04878432
What this trial is testing

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 39
Early research (Phase 1)Study completedNCT04641871
What this trial is testing

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Who this might be right for
Metastatic CancerSolid Tumor
Symphogen A/S 78
Early research (Phase 1)UnknownNCT05924906
What this trial is testing

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumor
Suzhou Neologics Bioscience Co., Ltd. 30
Early research (Phase 1)Looking for participantsNCT05357651
What this trial is testing

Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

Who this might be right for
Solid TumorLymphoma
L & L Bio Co., Ltd., Ningbo, China 100
Not applicableStudy completedNCT01801839
What this trial is testing

Detection Of Monocytes/Macrophages Function And Tim-3 Expression In Septic Patients

Who this might be right for
SepsisSIRS(Systemic Inflammatory Response Syndrome)
Chinese PLA General Hospital 1
Early research (Phase 1)Study completedNCT03311412
What this trial is testing

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Who this might be right for
Metastatic CancerSolid TumorLymphoma
Symphogen A/S 89
Testing effectiveness (Phase 2)Ended earlyNCT03946670
What this trial is testing

MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 127
Next Page